Profile data is unavailable for this security.
About the company
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
- Revenue in USD (TTM)65.18bn
- Net income in USD20.64bn
- Incorporated1901
- Employees50.00k
- LocationEli Lilly and CoLilly Corporate Ctr, Drop Code 1094INDIANAPOLIS 46285United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Mergers & acquisitions
| Acquired company | LLY:NYQ since announced | Transaction value |
|---|---|---|
| Orna Therapeutics Inc | -5.35% | 2.40bn |
| Ventyx Biosciences Inc | -5.87% | 1.01bn |
| Adverum Biotechnologies Inc | 21.99% | 274.32m |
| Verve Therapeutics Inc | 24.02% | 1.25bn |
| SiteOne Therapeutics Inc | 40.33% | 1.00bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc | 36.75bn | 7.71bn | 207.92bn | 31.50k | 27.09 | 24.00 | 16.09 | 5.66 | 14.24 | 14.24 | 67.87 | 16.07 | 0.4029 | 1.62 | 4.49 | 1,166,698.00 | 8.45 | 7.90 | 11.52 | 10.18 | 70.89 | 71.81 | 20.98 | 20.55 | 0.8958 | 15.77 | 0.8631 | 74.82 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| Merck & Co Inc | 65.01bn | 18.25bn | 300.17bn | 75.00k | 16.69 | 5.71 | 12.44 | 4.62 | 7.28 | 7.28 | 25.93 | 21.26 | 0.512 | 2.33 | 5.90 | 866,813.30 | 14.38 | 11.33 | 18.53 | 14.83 | 77.14 | 74.45 | 28.09 | 21.08 | 1.30 | 27.85 | 0.4837 | 60.05 | 1.31 | 9.38 | 6.64 | 32.21 | -1.47 | 5.49 |
| AbbVie Inc | 61.16bn | 4.19bn | 414.21bn | 57.00k | 99.25 | -- | 33.15 | 6.77 | 2.36 | 2.36 | 34.50 | -1.85 | 0.4545 | 3.80 | 5.20 | 1,072,983.00 | 3.15 | 5.27 | 4.53 | 7.07 | 71.62 | 69.82 | 6.92 | 12.86 | 0.557 | 7.90 | 1.05 | 146.03 | 8.57 | 5.95 | -1.23 | -1.68 | 8.75 | 7.10 |
| Johnson & Johnson | 94.19bn | 26.80bn | 599.00bn | 138.20k | 22.51 | 7.34 | 17.46 | 6.36 | 11.04 | 11.04 | 38.78 | 33.86 | 0.4967 | 2.27 | 5.88 | 681,570.20 | 14.13 | 9.88 | 19.50 | 13.58 | 67.98 | 69.12 | 28.46 | 20.93 | 0.7655 | -- | 0.3702 | 65.67 | 6.05 | 2.67 | 97.67 | 14.04 | 7.62 | 5.25 |
| Eli Lilly And Co | 65.18bn | 20.64bn | 960.31bn | 50.00k | 44.34 | 36.25 | 42.42 | 14.73 | 22.96 | 22.96 | 72.48 | 28.09 | 0.6818 | 1.04 | 4.53 | 1,303,580.00 | 21.59 | 15.07 | 32.37 | 23.19 | 83.04 | 79.87 | 31.67 | 24.00 | 1.19 | 58.83 | 0.6157 | 44.59 | 44.70 | 21.58 | 94.90 | 27.22 | 39.84 | 15.18 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 73.94m | 7.82% |
| PNC Bank, NA (Investment Management)as of 31 Dec 2025 | 51.11m | 5.41% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 41.84m | 4.43% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 35.36m | 3.74% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 24.57m | 2.60% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 21.90m | 2.32% |
| Geode Capital Management LLCas of 31 Dec 2025 | 19.81m | 2.10% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 15.03m | 1.59% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 13.74m | 1.45% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 12.69m | 1.34% |
